Skip to main content
Delfa

← Trials/Trial dossier/NCT00099242

CompletedPhase 3

Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

Asset

Rivastigmine

Listed sites

75

Recruiting sites

-

Enrollment

1,040

Study population

Alzheimer’s disease

Key I/E criterion

•Alzheimer's disease

Primary endpoints

•Cognition•Global clinical impression of change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDCENA713D2320
NCT IDNCT00099242

Timeline

Milestones

Study start2003-11 (month precision)
Study first posted2004-12-10estimated
Study completion2006-01actual (month precision)
Last update posted2017-10-13actual

Assets

Drug assets

Rivastigmine

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years
Maximum age85 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Diagnosis of dementia of the Alzheimer's type
•Males, and females who are surgically sterile or one year postmenopausal
•A primary caregiver willing to accept responsibility for supervising the treatment

Exclusion criteria

•Any condition (other than Alzheimer's) that could explain patient's dementia
•An advanced, severe or unstable disease that may put the patient at special risk
•Current diagnosis of active, uncontrolled seizure disorder or unstable cardiovascular disease

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
3
Executive function / language
2
Global cognition
1
Function / daily living
1

Global cognition

1 endpoint
Secondary/protocol endpoint

Change from baseline at week 24 in global cognitive testing

change from baseline, improvement

Executive function / language

2 endpoints
Secondary/protocol endpoint

Change from baseline at week 24 in executive function

change from baseline, improvement

Secondary/protocol endpoint

Change from baseline at week 24 in attention

change from baseline, improvement

Function / daily living

1 endpoint
Secondary/protocol endpoint

Change from baseline at week 24 in activities of daily living

change from baseline, improvement

Other (unclassified)

3 endpoints
Primary/protocol endpoint/low confidence

Change in cognition from baseline at week 24

change from baseline, improvement

Primary/protocol endpoint/low confidence

Global clinical impression of change from baseline at week 24

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change from baseline at week 24 in behavioral symptoms

change from baseline, improvement

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.